经典骨髓增殖性肿瘤的遗传学基础与分子病理生理机制
经典骨髓增殖性肿瘤(MPN)的遗传学图景已基本阐明。JAK2、CALR和MPL等驱动突变异常激活细胞因子受体/JAK2通路及STAT等下游效应分子;JAK2V617F激活EPOR、G-CSFR和MPL三种主要髓系细胞因子受体,而CALR或MPL突变仅激活MPL,这解释了JAK2V617F与PV、ET和PMF相关,CALR和MPL突变见于ET和PMF。表观遗传调控、剪接和信号传导相关基因的其他突变与三种驱动突变协同,在PMF发病中起关键作用。MPN的异质性和预后由特定基因组景观决定,但种系易感性、炎症和衰老等非体细胞突变因素亦重要。
要点
- JAK2V617F激活EPOR、G-CSFR和MPL三种受体,CALR或MPL突变仅激活MPL
- JAK2V617F见于PV、ET和PMF,CALR和MPL突变见于ET和PMF
- TET2和DNMT3A突变参与疾病起始,可能先于JAK2V617F获得
核心结论
- 经典MPN的异质性和预后由特定基因组景观决定,即MPN驱动突变类型、与其他突变的关联及其获得顺序。
- 种系易感性、炎症和衰老等体细胞突变以外的因素在疾病起始和进展中起重要作用。
- 阐明这些环境因素对于更好理解MPN的精确发病机制将很重要。
研究设计与样本
- 综述,阐述经典MPN的遗传学基础与分子病理生理机制。
主要发现
- JAK2V617F激活红血球生成素受体、粒细胞集落刺激因子受体和MPL三种主要髓系细胞因子受体,而CALR或MPL突变仅局限于激活MPL。
- JAK2V617F与真性红细胞增多症、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)相关,CALR和MPL突变见于ET和PMF。
- 表观遗传调控基因TET2和DNMT3A突变参与疾病起始,可能先于JAK2V617F的获得。
- 表观遗传调控基因EZH2和ASXL1突变参与疾病起始和疾病进展;剪接机器突变主要见于PMF,与贫血或全血细胞减少的发生相关。
关键数值与推荐
- MPN驱动突变包括JAK2、钙网蛋白(CALR)和骨髓增殖性白血病病毒(MPL)基因突变,异常激活细胞因子受体/JAK2通路及STAT等下游效应分子。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin (CALR), and myeloproliferative leukemia virus (MPL), abnormally activate the cytokine receptor/JAK2 pathway and their downstream effectors, more particularly the STATs. The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MPL mutants are restricted to MPL activation. This explains why JAK2V617F is associated with polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whereas CALR and MPL mutants are found in ET and PMF. Other mutations in genes involved in epigenetic regulation, splicing, and signaling cooperate with the 3 MPN drivers and play a key role in the PMF pathogenesis. Mutations in epigenetic regulators TET2 and DNMT3A are involved in disease initiation and may precede the acquisition of JAK2V617F. Other mutations in epigenetic regulators such as EZH2 and ASXL1 also play a role in disease initiation and disease progression. Mutations in the splicing machinery are predominantly found in PMF and are implicated in the development of anemia or pancytopenia. Both heterogeneity of classical MPNs and prognosis are determined by a specific genomic landscape, that is, type of MPN driver mutations, association with other mutations, and their order of acquisition. However, factors other than somatic mutations play an important role in disease initiation as well as disease progression such as germ line predisposition, inflammation, and aging. Delineation of these environmental factors will be important to better understand the precise pathogenesis of MPN.
引用
- Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2016. PMID: 28028029. doi:10.1182/blood-2016-10-695940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。